Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 289

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 289
---
000 — 5,000 — Operating expenses:Research and development9,061 6,945 14,879 17,482 Selling, general and administrative12,796 7,407 23,909 12,958 Total operating expenses21,857 14,352 38,788 30,440 Loss from operations(16,857)(14,352)(33,788)(30,440)Other income:Other income199 1,635 188 287 Interest income2,246 2,463 4,569 3,251 Total other income, net2,445 4,098 4,757 3,538 Net loss before income taxes(14,412)(10,254)(29,031)(26,902)Income tax expense500 — 500 — Net loss$(14,912)$(10,254)$(29,531)$(26,902)Other comprehensive loss:Unrealized loss on marketable securities(85)(61)(158)(68)Comprehensive loss$(14,997)$(10,315)$(29,689)$(26,970)Net loss per share, basic and diluted$(0.53)$(0.40)$(1.06)$(1.77)Weighted-average common shares outstanding, basic and diluted (1)28,079,07125,608,59427,804,11215,163,103

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

(1)See Note 2 for further information on weighted-average common shares outstanding.

2

Table of Contents

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY

(in thousands, except share data)

(unaudited)

Stockholders' EquityCommon StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)Stockholders' EquitySharesAmountBalance as of December 31, 202427,518,439$1 $348,901 $(145,014)$196 $204,084 Exercise of stock options and common warrants11,630— 44 — — 44 Unrealized loss on marketable securities—— — — (73)(73)Vesting of early exercised stock options5,594— 19